Yuhan Corporation

Abclon Inc.

Kyu-Tae Kim

Jong-Seo Lee

Bong-Kook Ko

June Hyung Lee

Ju Young Park

Ki Hong Kim

Moo Young Song

Eun-Jung Lee

Byung Hyun Choi

Na Rae Lee

Young Bong Park

Eunjeong Jeong

Kwang-Hoon Lee

Hyun-Jong Lee

Sunghyun Choi

Nakho Chang

In-Sik Hwang

Sook-Yeon Lee

Young-Ha Lee

Jong-Ho Lee

Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition. The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.

Anti-TIGIT antibodies and uses thereof

The present invention relates to HER2 (Human Epidermal Growth Factor Receptor 2) antibodies to prevent or treat cancers. The antibodies of the invention binds specifically to HER2 over-expressed in cancer cells (particularly, breast cancer and stomach cancer cells), specifically to an epitope on HER2 being different from epitope for trastuzumab. The CDR sequences of the present antibodies exhibit low similarity to CDR sequences of publicly known HER2 antibodies, addressing that the CDR sequences are unique. The antibodies of the present invention in combination with trastuzumab kill cancer cells with significantly enhanced cytotoxicity and therefore very effective in therapy of cancer (particularly, breast cancer and stomach cancer). Without wishing to be bound by theory, the enhanced efficacies of the combined therapy would address that the antibodies of the present invention bind to epitope on HER2 being different from epitope for trastuzumab, and inhibit HER2 in a cooperative manner with trastuzumab.

Antibody specifically binding to HER2

Growing community of inventors

Seoul, South Korea

Kyu-Tae Kim